Abstract
There has been recent interest in the use of the phosphodiesterase-5 inhibitor sildenafil for treating pulmonary hypertension. We examined the interaction between inhaled nitric oxide (iNO) and i.v. sildenafil in 12 piglets with acute pulmonary hypertension and lung injury secondary to meconium aspiration. Six animals (controls) received no intervention after meconium instillation, and six received iNO (20 ppm) from 120 min, with the addition at 240 min of an i.v. sildenafil infusion (2 mg/kg over 2 h). Meconium instillation increased mean pulmonary artery (PA) pressure from 16.0 ± 3.1 to 24.8 ± 4.6 mm Hg (p < 0.01) and pulmonary vascular resistance (PVR) from 0.047 ± 0.008 to 0.089 ± 0.027 mm Hg · ml−1 · min−1 · kg−1 (p < 0.01). Oxygenation index increased from 3 ± 0.8 to 8.3 ± 3.0 (p < 0.01). There were no further changes beyond 120 min in controls. iNO reduced PA pressure and PVR to baseline values, without influencing oxygenation. The addition of sildenafil further reduced PA pressure, tended to increase the cardiac output, and reduced PVR from 0.049 ± 0.02 to 0.028 ± 0.01 mm Hg · ml−1 · min−1 · kg−1 (p < 0.05). Sildenafil lowered the systemic blood pressure and systemic vascular resistance and produced profound arterial hypoxemia, reducing arterial Po2 from 69 ± 23 mm Hg to 49 ± 15 mm Hg, despite substantial increases first in inspired oxygen fraction and subsequently in mean airway pressures. Consequently, the oxygenation index increased by 13.9 ± 4.8 (p = 0.01). When given in addition to iNO, sildenafil at a dose of >0.5 mg/kg produced profound pulmonary vasodilation, but this was coupled with an unacceptable deterioration in oxygenation and systemic vasodilation in this model of pulmonary hypertension with acute parenchymal lung disease.
Similar content being viewed by others
Log in or create a free account to read this content
Gain free access to this article, as well as selected content from this journal and more on nature.com
or
Abbreviations
- SVR:
-
systemic vascular resistance
- PVR:
-
pulmonary vascular resistance
- Fio2:
-
inspired oxygen fraction
- CVP:
-
central venous pressure
- PAP:
-
mean pulmonary artery pressure
- PCWP:
-
mean pulmonary capillary wedge pressure
- OI:
-
oxygenation index
- iNO:
-
inhaled nitric oxide
- PAW:
-
airway pressure
References
Rimensberger PC, Spahr-Schopfer I, Berner M, Jaeggi E, Kalangos A, Friedli B, Beghetti M 2001 Inhaled nitric oxide versus aerosolized iloprost in secondary pulmonary hypertension in children with congenital heart disease: vasodilator capacity and cellular mechanisms. Circulation 103: 544–548
Clark RH, Kueser TJ, Walker MW, Southgate WM, Huckaby JL, Perez JA, Roy BJ, Keszler M, Kinsella JP 2000 Low-dose nitric oxide therapy for persistent pulmonary hypertension of the newborn. N Engl J Med 342: 469–474
Hasuda T, Satoh T, Shimouchi A, Sakamaki F, Kyotani S, Matsumoto T, Goto Y, Nakanishi N 2000 Improvement in exercise capacity with nitric oxide inhalation in patients with precapillary pulmonary hypertension. Circulation 10: 2066–2070
Goldman AP, Delius RE, Deanfield JE, de Leval MR, Sigston PE, Macrae DJ 1996 Nitric oxide might reduce the need for extracorporeal support in children with critical postoperative pulmonary hypertension. Ann Thorac Surg 62: 750–755
Dukarm RC, Russell JA, Morin FC, Perry BJ, Steinhorn RH 1999 The cGMP-specific phosphodiesterase inhibitor E4021 dilates the pulmonary circulation. Am J Respir Crit Care Med 160: 858–865
Zhao L, Mason NA, Morrell NW, Kojonazarov B, Sadykov A, Maripov A, Mirrakhimov MM, Aldashev A, Wilkins MR 2001 Sildenafil inhibits hypoxia-induced pulmonary hypertension. Circulation 104: 424–428
Prasad S, Wilkinson J, Gatzoulis MA 2000 Sildenafil in primary pulmonary hypertension. N Engl J Med 343: 1342
Abrams D, Schulze-Neick I, Magee AG 2000 Sildenafil as a selective pulmonary vasodilator in childhood primary pulmonary hypertension. Heart 84: E4
Bigatello LM, Hess D, Dennehy KC, Medoff BD, Hurford WE 2000 Sildenafil can increase the response to inhaled nitric oxide. Anesthesiology 92: 1827–1829
Atz AM, Lefler AK, Fairbrother DL, Uber WE, Bradley SM 2002 Sildenafil augments the effect of inhaled nitric oxide for postoperative pulmonary hypertensive crises. J Thorac Cardiovasc Surg 124: 628–629
Atz AM, Wessel DL 1999 Sildenafil ameliorates effects of inhaled nitric oxide withdrawal. Anesthesiology 91: 307–310
Shekerdemian LS, Ravn HB, Penny DJ 2002 Intravenous sildenafil lowers the pulmonary vascular resistance in a model of neonatal meconium aspiration. Am J Respir Crit Care Med 165: 1098–1102
Mercier JC, Lacaze T, Storme L, Roze JC, Dinh-Xuan AT, Dehan M 1998 Disease-related response to inhaled nitric oxide in newborns with severe hypoxaemic respiratory failure. French Paediatric Study Group of Inhaled NO. Eur J Pediatr 157: 747–752
Thusu KG, Morin FC, Russell JA, Steinhorn RH 1995 The cGMP phosphodiesterase inhibitor zaprinast enhances the effect of nitric oxide. Am J Respir Crit Care Med 152: 1605–1610
Weimann J, Ullrich R, Hromi J, Fujino Y, Clark MW, Bloch KD, Zapol WM 2000 Sildenafil is a pulmonary vasodilator in awake lambs with acute pulmonary hypertension. Anesthesiology 92: 1702–1712
Thebaud B, Saizou C, Farnoux C, Hartman JF, Mercier JC 1999 Dypiridamole, a cGMP phosphodiesterase inhibitor, transiently improves the response to inhaled nitric oxide in two newborns with congenital diaphragmatic hernia. Intensive Care Med 25: 300–303
Adrie C, Holzmann A, Hirani WM, Zapol WM, Hurford WE 2000 Effects of intravenous Zaprinast and inhaled nitric oxide on pulmonary hemodynamics and gas exchange in an ovine model of acute respiratory distress syndrome. Anesthesiology 93: 422–430
Kleinsasser A, Loeckinger A, Hoermann C, Puehringer F, Mutz N, Bartsch G, Lindner KH 2001 Sildenafil modulates hemodynamics and pulmonary gas exchange. Am J Respir Crit Care Med 163: 339–343
Dukarm RC, Morin FC, Russell JA, Steinhorn RH 1998 Pulmonary and systemic effects of the phosphodiesterase inhibitor dipyridamole in newborn lambs with persistent pulmonary hypertension. Pediatr Res 44: 831–837
Finer NN, Barrington KJ 2001 Nitric oxide for respiratory failure in infants born at or near term. Cochrane Database Syst Rev ( 4): CD000399
Schulze-Neick I, Hartenstein P, Li J, Stiller B, Nagdyman N, Hubler M, Butrous G, Petros A, Lange P, Redington AN 2003 Intravenous sildenafil is a potent pulmonary vasodilator in children with congenital heart disease. Circulation 180: II167–II173
Walker DK, Ackland MJ, James GC, Muirhead GJ, Rance DJ, Wastall P, Wright PA 1999 Pharmacokinetics and metabolism of sildenafil in mouse, rat, rabbit, dog and man. Xenobiotica 29: 297–310
Author information
Authors and Affiliations
Corresponding author
Additional information
This research was supported with a grant from The University of Aarhus, Denmark.
Rights and permissions
About this article
Cite this article
Shekerdemian, L., Ravn, H. & Penny, D. Interaction between Inhaled Nitric Oxide and Intravenous Sildenafil in a Porcine Model of Meconium Aspiration Syndrome. Pediatr Res 55, 413–418 (2004). https://doi.org/10.1203/01.PDR.0000112033.81970.C2
Received:
Accepted:
Issue date:
DOI: https://doi.org/10.1203/01.PDR.0000112033.81970.C2
This article is cited by
-
Life-threatening PPHN refractory to nitric oxide: proposal for a rational therapeutic algorithm
European Journal of Pediatrics (2021)
-
Emerging role of sildenafil in neonatology
Indian Pediatrics (2011)
